Author:
Pisula Agata,Sienicka Agnieszka,Dobrowolska-Redo Agnieszka,Kacperczyk-Bartnik Joanna,Romejko-Wolniewicz Ewa
Abstract
Ovarian cancer is responsible for the highest number of deaths of all female genital cancers. It is ranked as the sixth in the incidence and fourth in the mortality rate of malignant tumours in women in Poland. The disease is initially asymptomatic, which is why it is usually detected at advanced stages. More than 70% of ovarian cancer cases are detected at the stage III or IV according to the FIGO classification. The treatment of ovarian cancer is mainly based on surgery combined with systemic treatment (chemotherapy based on platinum derivatives and taxanes). Although most patients achieve a good response to first-line chemotherapy, there is usually a recurrence and drug resistance at a later stage, and the prognosis for recurrence is poor. PARP (Poly ADP-ribose polymerase) inhibitors are a new class of oral anticancer drugs that target DNA repair pathways and have shown promising efficacy in ovarian cancer patients in recent clinical trials. Olaparib, rucaparib and niraparib are innovative drugs currently changing clinical practice in ovarian cancer patients.
Publisher
Warszawski Uniwersytet Medyczny
Reference19 articles.
1. Didkowska, J.A.; Wojciechowska, U., Barańska, K.; Miklewska, M.; Michałek, I.; Olasek, P. Nowotwory złośliwe w Polsce w 2021 roku. Raport roczny. Narodowy Instytut Onkologii. Krajowy Rejestr Nowotworów. Warszawa 2023. ISSN 0867-8251
2. Basta, A. et al., Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of ovarian cancer. Curr. Gyn. Oncol. 2017, 15, 5-23.
3. Jassem, J.; Kordek, R. Onkologia. Podręcznik dla studentów i lekarzy. Ed. 5. 2019. Via Medica. 243-249
4. Zheng, F. et al. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Biomed. Pharmacother. 2020, 123, Art. No: 109661. doi: 10.1016/j.biopha.2019.10966
5. Herceg, Z.; Wang, Z.-Q. Functions of poly(ADP-ribose)polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat. Res. 2001, 477(1-2), 97-110. doi: 10.1016/s0027-5107(01)00111-7.